Key Artemisinin Antimalarial Drugs Market Players:
- Cipla Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Rusan Pharma Ltd.
- Sanofi S.A.
- Shin Poong Pharmaceutical Co., Ltd.
- Guilin Pharmaceutical Co., Ltd.
- Ipca Laboratories Ltd.
- KPC Pharmaceuticals, Inc.
- AdvaCare Pharma USA LLC
- Calyx Chemicals and Pharmaceuticals Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd
- Ajanta Pharma Limited
- Shanghai Desano Pharmaceutical Group Co., Ltd
- Mylan N.V.
- Shanghai Fosun Pharmaceutical Co., Ltd.
Key players in the artemisinin antimalarial drugs market are investing heavily in the development of new formulations and delivery systems to enhance efficacy and patient compliance. They are also innovating fixed-dose combination therapies, which could enhance the effectiveness of treatment and aid in combating resistance. Industry giants are also collaborating with other players and research organizations to foster innovation and boost drug development. Furthermore, they are expanding into high-potential regions such as Asia Pacific, and Middle East & Africa where malaria prevalence is high to earn high profits.
Some of the key players include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of artemisinin antimalarial drugs is evaluated at USD 715.66 million.
Artemisinin Antimalarial Drugs Market size was valued at USD 680.16 million in 2025 and is set to exceed USD 1.2 billion by 2035, registering over 5.8% CAGR during the forecast period i.e., between 2026-2035.
MEA’s 33.8% share in the artemisinin antimalarial drugs market is driven by the high prevalence of malaria, sustaining dominance through 2026–2035.
Key players in the market include Cipla Limited, Novartis AG, Sanofi S.A., GlaxoSmithKline Pharmaceuticals Ltd, Shanghai Desano Pharmaceutical Group Co., Ltd, Mylan N.V., and Shanghai Fosun Pharmaceutical Co., Ltd.
